Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...
Reexamination Certificate
2004-05-06
2008-10-21
Foley, Shanon A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds bacterium or component thereof or substance produced...
C424S184100, C435S069100, C435S252300, C435S320100, C435S325000, C536S023700, C530S300000, C530S350000
Reexamination Certificate
active
07438912
ABSTRACT:
The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof fromS. agalactiae, methods for isolating such antigens and specific uses thereof.
REFERENCES:
patent: WO 02/059148 (2002-08-01), None
Stalhammar-Carlemalm et al J.Exp.Med. 1993, 177, 1593-1603.
Ellis, R.W. (Chapter 29 of “Vaccines” Plotkin, 5.A. et al. (eds) published by W. B. Saunders company (Philadelphia) in 1988.
Accession nuber ABP28545.
Accession No. ADV88412.
Brodeur et al., “Identification of group B streptococcal Sip protein, which elicites cross-protective immunity,”Infection and Immunity, 68:5610-5618, 2000.
Database EMBL accession No. AE14198.
Database EMBL accession No. AL766844.
Etz et al., “Identification of in vivo expressed vaccine candidate antigens fromStaphyolococcus aureus,” Proc. Natl. Acad. Sci. USA, 99:6573-6578, 2002.
Glaser et al., “Genome sequence ofStreptococcus agalactia, a pathogen causing invasive neonatal disease,”Molecular Microbiology, 45:1499-1513, 2002.
Henics et al., “Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens,”Biotechniques, 35:196-200,202,20, 2003.
Hughes et al., “Novel protein vaccine candidates against Group B streptococcal infection identified using alkaline phosphate fusions,”FEMS Microbiology Letters, 222:263-271, 2003.
Klade, “Proteomics approaches towards antigen discovery in vaccine development,”Current Opinion in Molecular Therapeutics, 4:216-224, 2002.
Larsson et al., “Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine,”Vaccine, 17:454-458, 1999.
Michel et al., “Cloned alpha and beta C-protein antigens of group B Streptococci elicit protective immunity,”Infection and Immunity, 59:2023-2028, 1991.
Moyo et al., “The putative R1 protein of streptococcus agalactiae as serotype marker and target of protective antibodies,”APMIS, 109:842-848, 2001.
Tettelin et al., “Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype VStreptococcus agalactiae,” Proc. Natl. Acad. Sci. USA, 99:12391-12396, 2002.
Hanner Markus
Horky Markus
Kallenda Sabine
Meinke Andreas
Nagy Eszter
Baskar Padma V
Foley Shanon A.
Fulbright & Jaworski LLP
Intercell AG
LandOfFree
S.agalactiae antigens I + II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S.agalactiae antigens I + II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S.agalactiae antigens I + II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4007958